An analysis of the association between statin use and risk of endometrial and ovarian cancers in the Women's Health Initiative

Pinkal Desai; Robert Wallace; Matthew L. Anderson; Barbara V. Howard; Roberta M. Ray; Chunyuan Wu; Monika Safford; Lisa W. Martin; Thomas Rohan; JoAnn E. Manson; Michael S. Simon

doi:10.1016/j.ygyno.2018.01.006

Back

An analysis of the association between statin use and risk of endometrial and ovarian cancers in the Women's Health Initiative

Journal article

Open access

Peer reviewed

An analysis of the association between statin use and risk of endometrial and ovarian cancers in the Women's Health Initiative

Pinkal Desai, Robert Wallace, Matthew L. Anderson, Barbara V. Howard, Roberta M. Ray, Chunyuan Wu, Monika Safford, Lisa W. Martin, Thomas Rohan, JoAnn E. Manson, …

Gynecologic oncology, Vol.148(3), pp.540-546

03/2018

DOI: 10.1016/j.ygyno.2018.01.006

PMCID: PMC5896309

PMID: 29422345

Files and links (1)

url

https://www.ncbi.nlm.nih.gov/pmc/articles/5896309View

Open Access

Abstract

Statins have anti proliferative activity in vitro against endometrial and ovarian cancer and can affect levels of reproductive hormones. We analyzed data from the Women's Health Initiative (WHI) to assess whether statins are associated with risk of endometrial and ovarian cancer. The WHI study included 161,808 postmenopausal women in which incident cases of endometrial (n = 1377) and ovarian cancer (n = 763) were identified over an average of 10.8 (SD + 3.3) years. Information on statin use and risk factors was collected at baseline and follow-up. Cox proportional hazards regression was used to calculate hazard ratios (HRs) with 95% confidence intervals (CIs) for the association of statin use and risk of endometrial and ovarian cancer. All statistical tests were two-sided. Statins were used at baseline by 7.5% women and by up to 25% at year nine. The multivariable adjusted HR for risk of endometrial cancer for baseline statin use was 0.74, 95% C.I. 0.59–0.94 and for ovarian cancer was 1.15, 95% C.I. 0.89–1.50. In time-dependent models, statins were not associated with endometrial cancer (HR 0.91, 95% C.I. 0.76–1.08) however there was an increased risk of ovarian cancer (HR 1.30, 95% CI 1.04–1.62), largely attributed to the effect of the hydrophilic statin, pravastatin (1.89, 95% CI 1.24–2.88). There was a reduction in risk of endometrial cancer among statin users at baseline but not in time-dependent models. Pravastatin use was associated with an increased risk of ovarian cancer. Analyses of larger numbers of cases are needed to evaluate these findings. •We analyzed statin use and incidence of endometrial & ovarian cancer using the Women's Health Initiative cohort.•We found no association between statin use and endometrial cancer.•We found increased risk of ovarian cancer with statin use particularly pravastatin use.

Endometrial Cancer

Ovarian Cancer

Statins

Details

Title: Subtitle: An analysis of the association between statin use and risk of endometrial and ovarian cancers in the Women's Health Initiative
Creators: Pinkal Desai - Cornell University
Robert Wallace - University of Iowa
Matthew L. Anderson - Baylor College of Medicine
Barbara V. Howard - Georgetown-Howard Universities Center for Clinical and Translational Science
Roberta M. Ray - Fred Hutch Cancer Center
Chunyuan Wu - Fred Hutch Cancer Center
Monika Safford - Cornell University
Lisa W. Martin - University of Alabama
Thomas Rohan - Albert Einstein College of Medicine
JoAnn E. Manson - Brigham and Women's Hospital
Michael S. Simon - The Barbara Ann Karmanos Cancer Institute
Resource Type: Journal article
Publication Details: Gynecologic oncology, Vol.148(3), pp.540-546
DOI: 10.1016/j.ygyno.2018.01.006
PMID: 29422345
PMCID: PMC5896309
NLM abbreviation: Gynecol Oncol
ISSN: 0090-8258
eISSN: 1095-6859
Publisher: Elsevier Inc
Language: English
Date published: 03/2018
Academic Unit: Epidemiology; Injury Prevention Research Center; Internal Medicine
Record Identifier: 9984363643302771

Metrics

24 Record Views

26 Times Cited - Web of Science